Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma sets 1-for-50 reverse stock split effective August 20, 2026

Mixed Impact 4 of 5 legal/regulatory Written later

Liminatus Pharma said it will carry out a 1-for-50 reverse stock split of its common stock, effective August 20, 2026, so its shares can meet Nasdaq's $1.00 minimum bid price. The company remains listed under a Nasdaq Panel exception, but it must show a $1.00 closing bid for at least ten consecutive trading days by September 3, 2026, and the company says it cannot assure it will do so.

Key points

  • Reverse split ratio of 1-for-50, with split-adjusted trading under LIMN on The Nasdaq Capital Market expected at the market open on August 21, 2026
  • New CUSIP number 53271X 207; fractional shares will be rounded up to the nearest whole share, with no cash paid for fractions
  • Based on July 2, 2026 figures, outstanding shares would fall from 67,160,362 to approximately 1,343,208
  • Nasdaq Panel extended the deadline to demonstrate compliance with Listing Rule 5550(a)(2) to September 3, 2026

The filing

CompanyLiminatus Pharma, Inc. (LIMN)
Form8-K, current report
Filed with the SECAug 18, 2026, 4:06 PM ET
Accession number0001104659-26-098335

Items reported: 3.01 Delisting / Listing Rule Notice3.03 Change to Shareholder Rights5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.